(Seoul = Yonhap News) Reporter Koo Jeong-mo = American conglomerate Johnson & Johnson (J&J) announced on the 26th (local time) that the results of a phase 3 clinical trial of a novel coronavirus infection (Corona 19) vaccine will be released early next week.
According to the Wall Street Journal (WSJ), Johnson & Johnson delivered the news about the Corona 19 vaccine at the quarterly earnings announcement on the day, and expected to be able to supply 100 million doses of the vaccine to the United States by the end of June if approved by the authorities.
Alex Gorsky, the company’s CEO, said he was optimistic about the results of the clinical trial conducted on 45,000 people.
The journal said that the results of this clinical trial may provide clues to whether Johnson & Johnson’s vaccine is effective against the recently controversial COVID-19 mutation. Among the subjects of the clinical trial, there was a resident of South Africa with a confirmed mutation of COVID-19, which is highly contagious.
The journal evaluated that Johnson & Johnson’s vaccine had the advantage of being able to benefit from immunity and refrigerated storage with a single dose.
Pfizer and Modena vaccines currently on the market have to be inoculated twice, frozen, and defrosted before inoculation.
Johnson & Johnson announced on the same day that sales in the fourth quarter of last year increased by 8.3% from the same period last year ($2.75 billion) to $2.28 billion (about 24.69 trillion) thanks to the increase in sales in the pharmaceutical sector. This was above the market forecast of $21.6 billion.
Quarterly net income was $1.74 billion (1.91 trillion won), and earnings per share were 65 cents, both down from $4.10 billion and $1 50 cents a year ago.
[연합뉴스TV 제공]
Unauthorized reproduction-prohibition of redistribution>
2021/01/27 10:21 sent